Merger Madness Bastille Day 2025: From Biotech to Blockchain, AI Gaming, and Bots—Wall Street’s Wild New Frontier

July 14, 2025

DENVER, Colo., Jul 14, 2025 (247marketnews.com)- By any measure, July 2025 has become a landmark moment in the ongoing evolution of capital markets.

From BioTherapeutics to Blockchain: Sonnet’s Sudden HYPE Turn

In perhaps the most head-turning pivot of the year, Sonnet BioTherapeutics (NASDAQ:SONN) is swapping pipettes for private keys. The biotech microcap signed a definitive merger agreement with Rorschach I LLC, a crypto-heavy vehicle backed by Atlas Merchant Capital and Paradigm, to create Hyperliquid Strategies Inc. (HSI), the soon-to-be-largest U.S.-listed company holding HYPE, the native token of the Hyperliquid Layer-1 blockchain.

A company once focused on cancer immunotherapies is now poised to become a public crypto treasury, expected to hold 12.6 million HYPE tokens, valued at roughly $583 million and $305 million in cash, for a total assumed closing value of $888 million.

While Sonnet’s biotech arm will continue as a wholly owned subsidiary focused on SON-1010, legacy shareholders will hold just 1.2% of the combined company post-transaction. In return, common shareholders will receive a CVR tied to Sonnet’s existing pipeline.

Siyata Levels Up with Core Gaming Deal

Siyata Mobile (NASDAQ:SYTA) is taking a sharp turn from push-to-talk hardware into AI-powered digital entertainment. The company recently filed a Form 6-K signaling that its $185 million merger with Core Gaming, an AI gaming juggernaut with 43 million monthly active users, is nearing the finish line.

Core Gaming CEO Aitan Zacharin is set to lead the combined company and has pledged at least 10% equity retention for legacy Siyata shareholders. With an ambition to hit $100 million in combined revenue in 2025 and achieve profitability, the Core Gaming merger could catapult Siyata from obscurity into one of the hottest new AI-media plays on the market.

The regulatory breadcrumbs suggest the merger is imminent. If completed, this will mark one of the most aggressive business model shifts seen on the Nasdaq this year and perhaps, the most commercially ambitious.

Zimmer Biomet Goes Fully Autonomous with Monogram Buy

Not to be outdone, Zimmer Biomet (NYSE:ZBH) is reinforcing its position as a surgical robotics powerhouse with its $177 million acquisition of Monogram Technologies (NASDAQ:MGRM), a deal sweetened with a CVR worth up to $12.37 per share if long-term milestones are met.

The draw? Monogram’s FDA-cleared AI-guided total knee arthroplasty robot, with fully autonomous capabilities in development. If successfully integrated, Zimmer Biomet will be the first company in orthopedics to offer such a device, turning science fiction into surgical fact.

The transaction is expected to be earnings-neutral through 2027 but accretive thereafter, and it will immediately expand Zimmer’s already robust ROSA Robotics suite. As the company aims to roll out ROSA Knee with OptimiZe and new products like ROSA Shoulder, this deal locks in a decade of growth potential in one of healthcare’s fastest-growing segments.

Beyond the Deal Frenzy: Biotech and Battery Buzz

While merger headlines dominate the week, BiomX (NYSE:PHGE) is quietly making strides in the clinic. The company announced it has successfully initiated patient dosing in its Phase 2b trial of BX004, a precision phage therapy targeting Pseudomonas aeruginosa infections in cystic fibrosis (CF) patients. These infections remain a leading cause of death despite current treatment options.

With topline data expected in Q1 2026, BX004 could emerge as the leading phage-based treatment for this deadly pulmonary condition. The trial marks a significant milestone for the field of phage therapy, an area of growing scientific and investor interest as antibiotic resistance continues to mount.

Meanwhile, in the energy space, Stardust Power Inc. (NASDAQ:SDST) is catching momentum as investors flock to the lithium trade. The U.S.-based lithium developer is seeing renewed interest amid a broader rally in battery materials, positioning itself to benefit from the next wave of domestic EV supply chain development. As the lithium tide lifts the sector, Stardust is emerging as a potential breakout story in the race to electrify.

Please click here for a Deeper Dive on MAU Valuation Models, or insights from the ValueScope Report.

For additional 247marketnews.com Siyata disclosure https://247marketnews.com/syta-siyata-mobile-update/

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (SONN, SYTA, ZBH, MGRM, PHGE, SDST)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.